| scholarly article | Q13442814 |
| P356 | DOI | 10.2215/CJN.02271205 |
| P698 | PubMed publication ID | 17699309 |
| P50 | author | Andrea Doria | Q38544117 |
| Gianfranco Ferraccioli | Q41067658 | ||
| Gabriella Moroni | Q46463588 | ||
| P2093 | author name string | Claudio Ponticelli | |
| Carlo Manno | |||
| Marta Mosca | |||
| Ornella Della Casa Alberighi | |||
| Paolo Altieri | |||
| Roberto Ferrara | |||
| Silvano Todesco | |||
| Simona Greco | |||
| P433 | issue | 5 | |
| P921 | main subject | azathioprine | Q18939 |
| cyclosporine | Q367700 | ||
| lupus nephritis | Q1621830 | ||
| P304 | page(s) | 925-932 | |
| P577 | publication date | 2006-06-28 | |
| P1433 | published in | Clinical Journal of the American Society of Nephrology | Q15757929 |
| P1476 | title | A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years | |
| P478 | volume | 1 |
| Q42511206 | A decade of mycophenolate mofetil for lupus nephritis: is the glass half-empty or half-full? |
| Q36802101 | Adverse event burden, resource use, and costs associated with immunosuppressant medications for the treatment of systemic lupus erythematosus: a systematic literature review |
| Q36221407 | American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis |
| Q37960525 | Balancing efficacy and toxicity of novel therapies in systemic lupus erythematosus |
| Q87393398 | Chapter 12: Lupus nephritis |
| Q37892917 | Clearing the complexity: immune complexes and their treatment in lupus nephritis |
| Q88349367 | Comparative efficacy and safety of tacrolimus, mycophenolate mofetil, azathioprine, and cyclophosphamide as maintenance therapy for lupus nephritis : A Bayesian network meta-analysis of randomized controlled trials |
| Q39425959 | Con: The use of calcineurin inhibitors in the treatment of lupus nephritis |
| Q37954539 | Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report |
| Q38372154 | Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study |
| Q38059445 | Diagnosis and treatment of lupus nephritis flares--an update. |
| Q37804548 | Drug Monitoring in Systemic Lupus Erythematosus: A Systematic Review |
| Q35025425 | Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset |
| Q58204835 | Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice |
| Q51140299 | Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis. |
| Q44480906 | Established medications : new areas of application |
| Q53706807 | Glucocorticoids in the Treatment of Glomerular Diseases: Pitfalls and Pearls. |
| Q57689077 | Immunosuppressive treatment for proliferative lupus nephritis |
| Q55259113 | Interstitial inflammation and interstitial fibrosis and tubular atrophy predict renal survival in lupus nephritis. |
| Q36302245 | Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis |
| Q43031095 | Long-term outcomes--mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. |
| Q38608138 | Lupus nephritis: an update |
| Q84140353 | Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity |
| Q88644275 | Multitarget Therapy for Maintenance Treatment of Lupus Nephritis |
| Q43061715 | Mycophenolate mofetil for lupus nephritis |
| Q38585887 | Mycophenolate mofetil for lupus nephritis: an update |
| Q39835248 | New and emerging treatment approaches to lupus |
| Q36915693 | New treatment strategies for proliferative lupus nephritis: keep children in mind! |
| Q37356378 | Novel evidence-based systemic lupus erythematosus responder index |
| Q92625516 | Novel paradigms in systemic lupus erythematosus |
| Q84679599 | Oral cyclophosphamide is on the verge of extinction as therapy for severe autoimmune diseases (especially lupus): should nephrologists care? |
| Q38123242 | Overview of lupus nephritis management guidelines and perspective from Asia |
| Q38175076 | Overview of lupus nephritis management guidelines and perspective from Asia. |
| Q39425964 | Pro: The use of calcineurin inhibitors in the treatment of lupus nephritis |
| Q33924437 | Recent clinical trials in lupus nephritis |
| Q57945954 | References |
| Q38826018 | Remission and withdrawal of therapy in lupus nephritis. |
| Q37678723 | Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions. |
| Q55215256 | Risk of adverse events from different drugs for SLE: a systematic review and network meta-analysis. |
| Q93193261 | Systemic lupus erythematosus: Diagnosis and clinical management |
| Q34498515 | Systemic lupus erythematosus: review of synthetic drugs |
| Q37587317 | TAC-TIC use of tacrolimus-based regimens in lupus nephritis |
| Q45821336 | The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE. |
| Q90167554 | The Evolving Role of Calcineurin Inhibitors in Treating Lupus Nephritis |
| Q38925320 | The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review |
| Q35897121 | The effect of calcineurin inhibitors in the induction and maintenance treatment of lupus nephritis: a systematic review and meta-analysis |
| Q38285375 | The multifaceted aspects of refractory lupus nephritis |
| Q37715138 | The outcome of patients with lupus nephritis and the impact of cardiovascular risk factors |
| Q33598213 | The pathology of T cells in systemic lupus erythematosus |
| Q38686467 | Towards new avenues in the management of lupus glomerulonephritis |
| Q24202572 | Treatment for lupus nephritis |
| Q42728756 | Treatment of lupus nephritis |
| Q37822658 | Treatment of proliferative lupus nephritis: a slowly changing landscape |
| Q38271125 | Treatment of severe lupus nephritis: the new horizon. |
| Q38156915 | Treatment of young patients with lupus nephritis using calcineurin inhibitors |
| Q37288728 | Treatment options for proliferative lupus nephritis: an update of clinical trial evidence |
| Q36008840 | Understanding lupus nephritis: diagnosis, management, and treatment options |
| Q37255744 | Update on the management of lupus nephritis: let the treatment fit the patient |
Search more.